메뉴 건너뛰기
Drug Discovery Today
Volumn 10, Issue 1, 2005, Pages 14-17
Timely lessons for target-based discovery of anti-inflammatory drugs
Author keywords

Cell biology; Chemical Biology; Cyclooxygenase 2; Drug Discovery; Kinases; Matrix metalloproteinases; Pharmaceutical Science; Tuberculosis; Vioxx
Indexed keywords

ADALIMUMAB; ANTIINFLAMMATORY AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ETANERCEPT; INFLIXIMAB; NATALIZUMAB; ROFECOXIB;
EID: 12844255805     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03296-9     Document Type: Conference Paper
Times cited : (1)
References (9)
  • 1
    • 5444238963 scopus 로고    scopus 로고
    • Inflammation - The secret killer
    • February
    • Gorman C., Park A. Inflammation - the secret killer. Time Magazine. 163:2004;. February
    • (2004) Time Magazine , vol.163
    • Gorman, C.1    Park, A.2
  • 2
    • 6044267892 scopus 로고    scopus 로고
    • Failing the public health - Rofecoxib, Merck, and the FDA
    • Topol E.J. Failing the public health - rofecoxib, Merck, and the FDA. N. Engl. J. Med. 351:2004;1707-1709
    • (2004) N. Engl. J. Med , vol.351 , pp. 1707-1709
    • Topol, E.J.1
  • 3
    • 0036365355 scopus 로고    scopus 로고
    • Why drugs get pulled off the market
    • Meadows M. Why drugs get pulled off the market. FDA Consumer. 36:2002;11-17
    • (2002) FDA Consumer , vol.36 , pp. 11-17
    • Meadows, M.1
  • 4
    • 0035289779 scopus 로고    scopus 로고
    • Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
    • Lipinski C.A., et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46:2001;3-26
    • (2001) Adv. Drug Deliv. Rev , vol.46 , pp. 3-26
    • Lipinski, C.A.1
  • 5
    • 0036654725 scopus 로고    scopus 로고
    • Guiding molecules towards drug-likeness
    • Egan W.J., et al. Guiding molecules towards drug-likeness. Curr. Opin. Drug Discov. Devel. 5:2002;540-549
    • (2002) Curr. Opin. Drug Discov. Devel , vol.5 , pp. 540-549
    • Egan, W.J.1
  • 6
    • 0347949558 scopus 로고    scopus 로고
    • 'Me-too' products - Friend or foe?
    • Lee T.H. 'Me-too' products - friend or foe? N. Engl. J. Med. 350:2004;211-212
    • (2004) N. Engl. J. Med , vol.350 , pp. 211-212
    • Lee, T.H.1
  • 7
    • 1942500217 scopus 로고    scopus 로고
    • Is rheumatoid arthritis a consequence of natural selection for enhanced tuberculosis resistance?
    • Mobley J.L. Is rheumatoid arthritis a consequence of natural selection for enhanced tuberculosis resistance? Med. Hypotheses. 62:2004;839-843
    • (2004) Med. Hypotheses , vol.62 , pp. 839-843
    • Mobley, J.L.1
  • 8
    • 0142121432 scopus 로고    scopus 로고
    • Trends in development and approval times for new therapeutics in the United States
    • Reichert J.M. Trends in development and approval times for new therapeutics in the United States. Nat. Rev. Drug Discov. 2:2003;695-702
    • (2003) Nat. Rev. Drug Discov , vol.2 , pp. 695-702
    • Reichert, J.M.1
  • 9
    • 0033546665 scopus 로고    scopus 로고
    • TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study
    • Arnason B.G.W. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology. 53:1999;457-465
    • (1999) Neurology , vol.53 , pp. 457-465
    • Arnason, B.G.W.1

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.